Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway

The phosphoinositide 3-kinase pathway

Cantley, L. C. (2002) · Science · doi:10.1126/science.296.5573.1655 · Cited by 5,621

PTEN , a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer

Li, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S. I., Puc, J., Miliaresis, C., Rodgers, L., McCombie, R., et al. (1997) · Science · doi:10.1126/science.275.5308.1943 · Cited by 4,785

AMPK: a nutrient and energy sensor that maintains energy homeostasis

Hardie, D. G., Ross, F. A., & Hawley, S. A. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3311 · Cited by 4,602

Cellular survival: a play in three Akts

Datta, S. R., Brunet, A., & Greenberg, M. E. (1999) · Genes & Development · doi:10.1101/gad.13.22.2905 · Cited by 4,216

Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma

Hudes, G. R., Carducci, M. A., Tomczak, P., Dutcher, J. P., Figlin, R. A., Kapoor, A., Starosławska, E., Sosman, J. A., McDermott, D. F., Bodrogi, I., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066838 · Cited by 3,645

High Frequency of Mutations of the PIK3CA Gene in Human Cancers

Samuels, Y., Wang, Z., Bardelli, A., Silliman, N., Ptak, J., Szabo, S., Yan, H., Gazdar, A. F., Powell, S. M., Riggins, G. J., et al. (2004) · Science · doi:10.1126/science.1096502 · Cited by 3,448

The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism

Engelman, J. A., Luo, J., & Cantley, L. C. (2006) · Nature Reviews Genetics · doi:10.1038/nrg1879 · Cited by 3,330

The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate

Maehama, T., & Dixon, J. E. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.22.13375 · Cited by 3,104

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

Motzer, R. J., Escudier, B., Oudard, S., Hutson, T. E., Porta, C., Bracarda, S., Grünwald, V., Thompson, J. A., Figlin, R. A., Hollaender, N., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61039-9 · Cited by 3,019

Everolimus for Advanced Pancreatic Neuroendocrine Tumors

Yao, J. C., Shah, M. H., Ito, T., Lombard‐Bohas, C., Wolin, E. M., Cutsem, E. V., Hobday, T. J., Okusaka, T., Capdevila, J., de Vries, E. G. E., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009290 · Cited by 2,879

Protein restriction and cancer

Yin, J., Ren, W., Huang, X., Li, T., & Yin, Y. (2018) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.03.004 · Cited by 69

Scutellarin inhibits human renal cancer cell proliferation and migration via upregulation of PTEN

Deng, W., Han, W., Fan, T., Wang, X., Cheng, Z., Wan, B., & Chen, J. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.08.127 · Cited by 64

Advances in systemic lupus erythematosus pathogenesis via mTOR signaling pathway

He, J., Ma, J., Ren, B., & Liu, A. (2019) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2019.09.022 · Cited by 69

Phloretin induces cell cycle arrest and apoptosis of human glioblastoma cells through the generation of reactive oxygen species

Liu, Y., Fan, C., Lv, P., Wei, C., Jin, H., Teng, Y., Zhao, M., Yu, A. C., Jiang, F., Shu, J., et al. (2016) · Journal of Neuro-Oncology · doi:10.1007/s11060-016-2107-z · Cited by 61

Metabolic dysfunction and cancer in HCV: Shared pathways and mutual interactions

Leslie, J., Geh, D., Elsharkawy, A. M., Mann, D. A., & Vacca, M. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.01.029 · Cited by 61

PI3K/AKT Signaling Pathway Mediated Autophagy in Oral Carcinoma - A Comprehensive Review

Rajendran, P., Sekar, R., Shankar, D. P., Ali, E. M., Abdelsalam, S. A., Balaraman, S., Chellappan, B. V., Metwally, A. M., & Abdallah, B. M. (2024) · International Journal of Medical Sciences · doi:10.7150/ijms.94566 · Cited by 67

A comprehensively characterized large panel of head and neck cancer patient‐derived xenografts identifies the m TOR inhibitor everolimus as potential new treatment option

Klinghammer, K. F., Raguse, J. D., Plath, T., Albers, A. E., Joehrens, K., Zakarneh, A., Brzezicha, B., Wulf‐Goldenberg, A., Keilholz, U., Hoffmann, J., et al. (2014) · International Journal of Cancer · doi:10.1002/ijc.29344 · Cited by 64

Targeting Therapeutic Liabilities Engendered by PIK3R1 Mutations for Cancer Treatment

Cheung, L. W. T., & Mills, G. B. (2016) · Pharmacogenomics · doi:10.2217/pgs.15.174 · Cited by 62

A blockade of PD-L1 produced antitumor and antimetastatic effects in an orthotopic mouse pancreatic cancer model via the PI3K/AkT/MTOR signaling pathway

Zhao, L., Li, C., Liu, F., Zhao, Y., Liu, J., Hua, Y., Liu, J., Huang, J., & Ge, C. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s130481 · Cited by 61

Knockdown of hnRNP A2/B1 inhibits cell proliferation, invasion and cell cycle triggering apoptosis in cervical cancer via PI3K/AKT signaling pathway

Shi, X., Ran, L., Liu, Y., Zhong, S., Zhou, P., Liao, M., & Fang, W. (2018) · Oncology Reports · doi:10.3892/or.2018.6195 · Cited by 61

CK2 inhibition with silmitasertib promotes methuosis-like cell death associated to catastrophic massive vacuolization of colorectal cancer cells

Silva-Pavez, E., Villar, P., Trigo, C., Caamaño, E., Niechi, I., Pérez, P. E., Muñoz, J. P., Aguayo, F., Burzio, V. A., Varas‐Godoy, M., et al. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1306-x · Cited by 64

FABP5 regulates the proliferation of clear cell renal cell carcinoma cells via the PI3K/AKT signaling pathway

Lv, Q., Wang, G., Zhang, Y., Han, X., Li, H., Le, W., Zhang, M., Ma, C., Wang, P., & Ding, Q. (2019) · International Journal of Oncology · doi:10.3892/ijo.2019.4721 · Cited by 61

CADM1 inhibits ovarian cancer cell proliferation and migration by potentially regulating the PI3K/Akt/mTOR pathway

Si, X., Xu, F., Xu, F., Wei, M., Ge, Y., & Chenge, S. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109717 · Cited by 61

Solute Carrier Family 39 Member 6 Gene Promotes Aggressiveness of Esophageal Carcinoma Cells by Increasing Intracellular Levels of Zinc, Activating Phosphatidylinositol 3-Kinase Signaling, and Up-regulating Genes That Regulate Metastasis

Cheng, X., Wei, L., Huang, X., Zheng, J., Shao, M., Feng, T., Li, J., Han, Y., Tan, W., Tan, W., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.02.006 · Cited by 61

Negative regulators of cell death pathways in cancer: perspective on biomarkers and targeted therapies

Razaghi, A., Heimann, K., Schaeffer, P. M., & Gibson, S. B. (2018) · APOPTOSIS · doi:10.1007/s10495-018-1440-4 · Cited by 60

Triple negative breast cancer chemosensitivity and chemoresistance: current advances in biomarkers indentification

Guestini, F., McNamara, K. M., Ishida, T., & Sasano, H. (2016) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2016.1125469 · Cited by 58

Cell signaling pathways as molecular targets to eliminate AML stem cells

Rodrigues, A. C., Costa, R. G. A., Silva, S. L. R., Dias, I. R. S. B., Dias, R. B., & Bezerra, D. P. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103277 · Cited by 61

Long Non-Coding RNA XLOC_006753 Promotes the Development of Multidrug Resistance in Gastric Cancer Cells Through the PI3K/AKT/mTOR Signaling Pathway

Zeng, L., Liao, Q., Zou, Z., Wen, Y., Wang, J., Liu, C., He, Q., Weng, N., Zeng, J., Tang, H., et al. (2018) · Cellular Physiology and Biochemistry · doi:10.1159/000495499 · Cited by 57

Conjunctival Melanoma: Genetic and Epigenetic Insights of a Distinct Type of Melanoma

Rossi, E., Schinzari, G., Maiorano, B., Pagliara, M., Stefani, A. D., Bria, E., Peris, K., Blasi, M., & Tortora, G. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20215447 · Cited by 47

The novel mTOR inhibitor Torin-2 induces autophagy and downregulates the expression of UHRF1 to suppress hepatocarcinoma cell growth

Wang, C., WANG, X., Su, Z., Fei, H.-J., Liu, X., & Pan, Q. (2015) · Oncology Reports · doi:10.3892/or.2015.4146 · Cited by 57

Clinical use of PI3K inhibitors in B-cell lymphoid malignancies: today and tomorrow

Greenwell, I. B., Flowers, C. R., Blum, K. A., & Cohen, J. B. (2017) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2017.1285702 · Cited by 58

MicroRNA-708-5p acts as a therapeutic agent against metastatic lung cancer

Wu, X., Liu, T., Fang, O., Dong, W., Zhang, F., Leach, L. J., Hu, X., & Luo, Z. (2015) · Oncotarget · doi:10.18632/oncotarget.6594 · Cited by 58

Diosgenin-induced autophagy and apoptosis in a human prostate cancer cell line

Nie, C., Zhou, J., Qin, X., Shi, X., Zeng, Q., Liu, J., Yan, S., & Zhang, L. (2016) · Molecular Medicine Reports · doi:10.3892/mmr.2016.5750 · Cited by 56

27-hydroxycholesterol: A novel player in molecular carcinogenesis of breast and prostate cancer

Marwarha, G., Raza, S., Hammer, K. D. P., & Ghribi, O. (2017) · Chemistry and Physics of Lipids · doi:10.1016/j.chemphyslip.2017.05.012 · Cited by 59

Ganoderic acid A holds promising cytotoxicity on human glioblastoma mediated by incurring apoptosis and autophagy and inactivating PI3K/AKT signaling pathway

Cheng, Y. H., & Xie, P. (2019) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.22392 · Cited by 55

The de-ubiquitinase UCHL1 promotes gastric cancer metastasis via the Akt and Erk1/2 pathways

Gu, Y., Yang, M., Zhao, M., Luo, Q., Yang, L., Peng, H., Wang, J., Huang, S., Zheng, Z., Yuan, X., et al. (2015) · Tumor Biology · doi:10.1007/s13277-015-3566-0 · Cited by 55

PI3K-Akt signaling pathway upregulates hepatitis C virus RNA translation through the activation of SREBPs

Shi, Q., Hoffman, B. A., & Liu, Q. (2016) · Virology · doi:10.1016/j.virol.2016.01.012 · Cited by 55

PLGA-PEG nanoparticles for targeted delivery of the mTOR/PI3kinase inhibitor dactolisib to inflamed endothelium

Gholizadeh, S., Kamps, J. A. A. M., Hennink, W. E., & Kok, R. J. (2017) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2017.10.032 · Cited by 58

20(S)-Ginsenoside Rh2 displays efficacy against T-cell acute lymphoblastic leukemia through the PI3K/Akt/mTOR signal pathway

Xia, T., Zhang, J., Zhou, C., Li, Y., Duan, W., Zhang, B., Wang, M., & Fang, J. (2019) · Journal of Ginseng Research · doi:10.1016/j.jgr.2019.07.003 · Cited by 55

To Investigate the Occurrence and Development of Colorectal Cancer Based on the PI3K/AKT/mTOR Signaling Pathway

Zhong, J., Ding, S., Zhang, X., Di, W., Wang, X., Zhang, H., Chen, Y., Zhang, Y., & Hu, Y. (2023) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2802037 · Cited by 61

GPCR48/LGR4 promotes tumorigenesis of prostate cancer via PI3K/Akt signaling pathway

Liang, F., Yue, J., Wang, J., Zhang, L., Fan, R., Zhang, H., & Zhang, Q. (2015) · Medical Oncology · doi:10.1007/s12032-015-0486-1 · Cited by 54

Dual PI3K/mTOR inhibitor PKI-402 suppresses the growth of ovarian cancer cells by degradation of Mcl-1 through autophagy

Hu, X., Xia, M., Wang, J., Yu, H., Chai, J., Zhang, Z., Sun, Y., Su, J., & Sun, L. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110397 · Cited by 55

PD-1/PD-L1 enhanced cisplatin resistance in gastric cancer through PI3K/AKT mediated P-gp expression

Wu, L., Cai, S., Deng, Y., Zhang, Z., Zhou, X.-H., Su, Y., & Xu, D. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107443 · Cited by 56

Autophagy Takes Center Stage as a Possible Cancer Hallmark

Alvarez-Meythaler, J. G., Garcia‐Mayea, Y., Mir, C., Kondoh, H., & LLeonart, M. E. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.586069 · Cited by 59

Regulation of Cancer Metabolism by Deubiquitinating Enzymes: The Warburg Effect

Kim, S., & Baek, K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126173 · Cited by 59

Design, Synthesis, and Evaluation of Potent, Selective, and Bioavailable AKT Kinase Degraders

Yu, X., Xu, J., Xie, L., Wang, L., Shen, Y., Cahuzac, K. M., Chen, X., Liu, J., Parsons, R. E., & Jin, J. J. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01476 · Cited by 55

Danusertib Induces Apoptosis, Cell Cycle Arrest, and Autophagy but Inhibits Epithelial to Mesenchymal Transition Involving PI3K/Akt/mTOR Signaling Pathway in Human Ovarian Cancer Cells

Zi, D., Zhou, Z.-W., Yang, Y.-J., Huang, L., Zhou, Z.-L., He, S.-M., He, Z.-X., & Zhou, S.-F. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms161126018 · Cited by 52

Re-establishing the comprehension of phytomedicine and nanomedicine in inflammation-mediated cancer signaling

Jha, N. K., Arfin, S., Jha, S. K., Kar, R., Dey, A., Gundamaraju, R., Ashraf, G. M., Gupta, P. K., Dhanasekaran, S., Abomughaid, M. M., et al. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.02.022 · Cited by 54

Metformin plus sorafenib highly impacts temozolomide resistant glioblastoma stem-like cells.

Aldea, M. D., Petrushev, B., Şoriţău, O., Tomuleasa, C., Berindan‐Neagoe, I., Filip, G. A., Cherecheș, G., Cenariu, M., Craciun, L., Tatomir, C. B., et al. (2014) · PubMed · Cited by 51

Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy

Park, H., Garrido‐Laguna, I., Naing, A., Fu, S., Falchook, G. S., Piha-Paul, S. A., Wheler, J. J., Hong, D. S., Tsimberidou, A. M., Subbiah, V., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11750 · Cited by 51

Natural polyphenols for the prevention of irritable bowel syndrome: molecular mechanisms and targets; a comprehensive review

Roudsari, N. M., Lashgari, N., Momtaz, S., Farzaei, M. H., Marques, A. M., & Abdolghaffari, A. H. (2019) · DARU Journal of Pharmaceutical Sciences · doi:10.1007/s40199-019-00284-1 · Cited by 53

FBX8 is a metastasis suppressor downstream of miR-223 and targeting mTOR for degradation in colorectal carcinoma

Wang, F. F., Zhang, X. J., Yan, Y., Zhu, X., Yu, J., Ding, Y., Hu, J., Zhou, W., Zeng, Z., Liao, W., et al. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.11.031 · Cited by 51

Neuroglobin, a pro-survival player in estrogen receptor α-positive cancer cells

Fiocchetti, M., Nuzzo, M. T., Totta, P., Acconcia, F., Ascenzi, P., & Marino, M. (2014) · Cell Death and Disease · doi:10.1038/cddis.2014.418 · Cited by 52

The Role of Cetuximab in the Induction of Anticancer Immune Response in Colorectal Cancer Treatment

Holubec, L., Polívka, J., Šafanda, M., Karas, M., & Liška, V. (2016) · Anticancer Research · doi:10.21873/anticanres.10985 · Cited by 52

ANXA6 Contributes to Radioresistance by Promoting Autophagy via Inhibiting the PI3K/AKT/mTOR Signaling Pathway in Nasopharyngeal Carcinoma

Chen, Q., Wang, Z., Zhu, L., Yao, D., Wang, C., Song, Y., Hu, S., Liu, H., Bai, Y., Pan, Y., et al. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00232 · Cited by 50

Loss of Pten synergizes with c-Met to promote hepatocellular carcinoma development via mTORC2 pathway

Xu, Z., Hu, J., Cao, H., Pilo, M. G., Cigliano, A., Shao, Z., Xu, M. M., Ribback, S., Dombrowski, F., Calvisi, D. F., et al. (2018) · Experimental & Molecular Medicine · doi:10.1038/emm.2017.158 · Cited by 49

RTN4 Knockdown Dysregulates the AKT Pathway, Destabilizes the Cytoskeleton, and Enhances Paclitaxel-Induced Cytotoxicity in Cancers

Pathak, G. P., Shah, R., Kennedy, B. E., Murphy, J. P., Clements, D. R., Konda, P., Giacomantonio, M., Xu, Z., Schlaepfer, I. R., & Gujar, S. A. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.05.026 · Cited by 48

The Molecular Mechanism of Metabolic Remodeling in Lung Cancer

Chang, L., Fang, S., & Gu, W. (2020) · Journal of Cancer · doi:10.7150/jca.31406 · Cited by 49

Anethole improves the in vitro development of isolated caprine secondary follicles

de Sá, N. A. R., Araújo, V. R., Correia, H. H. V., Ferreira, A. C. A., Guerreiro, D. D., Sampaio, A., Escobar, E., Cibin, F. W. S., Moura, A. A., Lôbo, C. H., et al. (2015) · Theriogenology · doi:10.1016/j.theriogenology.2015.12.014 · Cited by 48

Hsa_circ_001569 is an unfavorable prognostic factor and promotes cell proliferation and metastasis by modulating PI3K-AKT pathway in breast cancer

Xu, J., Wang, Y., & Xu, D. (2019) · Cancer Biomarkers · doi:10.3233/cbm-182293 · Cited by 48

METTL14-mediated N6-methyladenosine modification of Pten mRNA inhibits tumour progression in clear-cell renal cell carcinoma

Zhang, L., Luo, X., & Qiao, S. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-01757-y · Cited by 48

Src acts as the target of matrine to inhibit the proliferation of cancer cells by regulating phosphorylation signaling pathways

Zhang, X., Xu, H., Bi, X., Hou, G., Liu, A., Zhao, Y., Wang, G., & Cao, X. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-04221-6 · Cited by 47

Lithium Modulates Autophagy in Esophageal and Colorectal Cancer Cells and Enhances the Efficacy of Therapeutic Agents In Vitro and In Vivo

O’Donovan, T. R., Rajendran, S., O’Reilly, S., O’Sullivan, G. C., & McKenna, S. L. (2015) · PLoS ONE · doi:10.1371/journal.pone.0134676 · Cited by 47

MicroRNA-21 promotes perineural invasion and impacts survival in patients with oral carcinoma

Yu, E., Tu, H., Wu, C., Yang, C., & Chang, K. (2017) · Journal of the Chinese Medical Association · doi:10.1016/j.jcma.2017.01.003 · Cited by 47

A fully coupled space–time multiscale modeling framework for predicting tumor growth

Rahman, M. M., Feng, Y., Yankeelov, T. E., & Oden, J. T. (2017) · Computer Methods in Applied Mechanics and Engineering · doi:10.1016/j.cma.2017.03.021 · Cited by 48

Putative biomarkers for cervical cancer: SNVs, methylation and expression profiles

Cardoso, M. D. F. S., Castelletti, C. H. M., de Lima-Filho, J. L., Martins, D. B. G., & Teixeira, J. A. (2017) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2017.06.002 · Cited by 47

Design, synthesis, and biological evaluation of novel 3-substituted imidazo[1,2- a ]pyridine and quinazolin-4(3H)-one derivatives as PI3Kα inhibitors

Fan, Y., Li, W., Liu, D., Bai, M., Song, H., Xu, Y., Lee, S.-K., Zhou, Z., Wang, J., & Ding, H. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.07.074 · Cited by 47

Overexpression of long noncoding RNA GAS5 suppresses tumorigenesis and development of gastric cancer by sponging miR-106a-5p through the Akt/mTOR pathway

Dong, S., Zhang, X., & Liu, D. (2019) · Biology Open · doi:10.1242/bio.041343 · Cited by 47

A combination of the PI3K pathway inhibitor plus cell cycle pathway inhibitor to combat endocrine resistance in hormone receptor-positive breast cancer: a genomic algorithm-based treatment approach.

Gul, A., Leyland-Jones, B., Dey, N., & De, P. K. (2018) · Europe PMC (PubMed Central) · Cited by 45

Comprehensive Proteomic Profiling of Aqueous Humor Proteins in Proliferative Diabetic Retinopathy

Xiao, H., Xin, W., Sun, L. M., Li, S. S., Zhang, T., & Ding, X. Y. (2021) · Translational Vision Science & Technology · doi:10.1167/tvst.10.6.3 · Cited by 46

Rhoifolin from Plumula Nelumbinis exhibits anti-cancer effects in pancreatic cancer via AKT/JNK signaling pathways

Zheng, B., Zheng, Y., Zhang, N., Zhang, Y., & Zheng, B. (2022) · Scientific Reports · doi:10.1038/s41598-022-09581-3 · Cited by 46

MAOA suppresses the growth of gastric cancer by interacting with NDRG1 and regulating the Warburg effect through the PI3K/AKT/mTOR pathway

Wang, Y., Zhou, Y.-Q., Xie, J.-X., Zhang, X., Wang, S., Li, Q., Hu, L.-P., Jiang, S., Yi, S., Xu, J., et al. (2023) · Cellular Oncology · doi:10.1007/s13402-023-00821-w · Cited by 46

ALK alteration is a frequent event in aggressive breast cancers

Siraj, A. K., Beg, S., Jehan, Z., Prabhakaran, S., Ahmed, M., Hussain, A. R., Al‐Dayel, F., Tulbah, A. M., Ajarim, D. S., & Al-Kuraya, K. S. (2015) · Breast Cancer Research · doi:10.1186/s13058-015-0610-3 · Cited by 46

Benzo(a)pyrene inhibits migration and invasion of extravillous trophoblast HTR‐8/SVneo cells via activation of the ERK and JNK pathway

Liu, L., Wang, Y., Shen, C., He, J., Liu, X., Ding, Y., Gao, R., & Chen, X. (2015) · Journal of Applied Toxicology · doi:10.1002/jat.3227 · Cited by 46

Bayesian Response-Adaptive Designs for Basket Trials

Ventz, S., Barry, W. T., Parmigiani, G., & Trippa, L. (2017) · Biometrics · doi:10.1111/biom.12668 · Cited by 46

Targeting the mTOR Signaling Pathway Utilizing Nanoparticles: A Critical Overview

Lunová, M., Smolková, B., Lynnyk, A., Uzhytchak, M., Jirsa, M., Kubinová, Š., Dejneka, A., & Lunov, O. (2019) · Cancers · doi:10.3390/cancers11010082 · Cited by 47

New Strategies in Personalized Medicine for Solid Tumors: Molecular Markers and Clinical Trial Designs

Jürgensmeier, J. M., Eder, J. P., & Herbst, R. S. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0753 · Cited by 46

Knockdown of tripartite motif 59 (TRIM59) inhibits proliferation in cholangiocarcinoma via the PI3K/AKT/mTOR signalling pathway

Shen, H., Zhang, J., Zhang, Y., Qinchao, F., Wang, H., Li, G., Jiang, W., & Li, X. (2019) · Gene · doi:10.1016/j.gene.2019.02.044 · Cited by 45

Identification of Key Biomarkers and Potential Molecular Mechanisms in Oral Squamous Cell Carcinoma by Bioinformatics Analysis

Yang, B., Dong, K., Guo, P., Guo, P., Jie, G., Zhang, G., & Li, T. (2019) · Journal of Computational Biology · doi:10.1089/cmb.2019.0211 · Cited by 44

Silencing of miR-17-5p suppresses cell proliferation and promotes cell apoptosis by directly targeting PIK3R1 in laryngeal squamous cell carcinoma

Wang, J.-X., Jia, X., Liu, Y., Dong, J., Ren, X., Xu, O., Liu, S., & Shan, C. (2020) · Cancer Cell International · doi:10.1186/s12935-020-1096-3 · Cited by 45

Taxifolin, Extracted from Waste Larix olgensis Roots, Attenuates CCl4-Induced Liver Fibrosis by Regulating the PI3K/AKT/mTOR and TGF-β1/Smads Signaling Pathways

Liu, X., Liu, W., Ding, C., Zhao, Y., Chen, X., Dong, L., Zheng, Y., & Cheng, Z. (2021) · Drug Design Development and Therapy · doi:10.2147/dddt.s281369 · Cited by 46

Small biomarkers with massive impacts: PI3K/AKT/mTOR signalling and microRNA crosstalk regulate nasopharyngeal carcinoma

Li, H., Deng, N.-H., Xiu-sheng, H., & Li, Y. (2022) · Biomarker Research · doi:10.1186/s40364-022-00397-x · Cited by 44

Pharmacological Effects and Clinical Prospects of Cepharanthine

Liang, D., Li, Q., Du, L., & Dou, G. (2022) · Molecules · doi:10.3390/molecules27248933 · Cited by 44

Cancer Protective Role of Selected Dietary Polyphenols via Modulating Keap1/Nrf2/ARE and Interconnected Signaling Pathways

Islam, M. A., Medha, M. M., Nahar, A. U., Fahad, M. A. A., Siraj, M. A., & Seidel, V. (2023) · Nutrition and Cancer · doi:10.1080/01635581.2023.2183546 · Cited by 45

Isobavachalcone induces the apoptosis of gastric cancer cells via inhibition of the Akt and Erk pathways

Jin, X., & Shi, Y. (2015) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2015.2904 · Cited by 43

Role of micro-RNAs in drug resistance of multiple myeloma

Abdi, J., Hou, J., & Chang, H. (2016) · Oncotarget · doi:10.18632/oncotarget.11032 · Cited by 44

microRNA‐10b confers cisplatin resistance by activating AKT/mTOR/P70S6K signaling via targeting PPARγ in esophageal cancer

Wu, K., Hu, Y., Yan, K., Qi, Y., Zhang, C., Dengyan, Z., Liu, D., & Zhao, S. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.29040 · Cited by 44

Combination Therapy and Nanoparticulate Systems: Smart Approaches for the Effective Treatment of Breast Cancer

Gadag, S., Sinha, S., Nayak, Y., Garg, S., & Nayak, U. Y. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12060524 · Cited by 46

The PI3K/Akt Signaling Pathway Mediates the High Glucose-Induced Expression of Extracellular Matrix Molecules in Human Retinal Pigment Epithelial Cells

Qin, D., Zhang, G., Xu, X., & Wang, L. (2015) · Journal of Diabetes Research · doi:10.1155/2015/920280 · Cited by 43

PKI-587 enhances chemosensitivity of oxaliplatin in hepatocellular carcinoma through suppressing DNA damage repair pathway (NHEJ and HR) and PI3K/AKT/mTOR pathway.

Zhang, Y., Xie, C., Li, A., Liu, X., Xing, Y., Shen, J., Huo, Z., Zhou, S., Liu, X., Xie, Y., et al. (2019) · Europe PMC (PubMed Central) · Cited by 42

MUC15 inhibits cancer metastasis via PI3K/AKT signaling in renal cell carcinoma

Yue, Y., Hui, K., Wu, S., Zhang, M., Que, T., Gu, Y., Wang, X., Wu, K., & Fan, J. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-2518-9 · Cited by 43

Ginsenoside Rg1-Notoginsenoside R1-Protocatechuic Aldehyde Reduces Atherosclerosis and Attenuates Low-Shear Stress-Induced Vascular Endothelial Cell Dysfunction

Zhang, L., Li, Y., Ma, X., Liu, J., Wang, X., Zhang, L., Li, C., Li, Y., & Yang, W. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.588259 · Cited by 42

RY-2f, an isoflavone analog, overcomes cisplatin resistance to inhibit ovarian tumorigenesis via targeting the PI3K/AKT/mTOR signaling pathway

Liu, M., Qi, Z., Liu, B., Ren, Y. A., Li, H., Yang, G. S., & Zhang, Q. (2015) · Oncotarget · doi:10.18632/oncotarget.4634 · Cited by 44

Targeted therapies in gastric cancer and future perspectives

Yazıcı, O. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i2.471 · Cited by 42

Gold-chrysophanol nanoparticles suppress human prostate cancer progression through inactivating AKT expression and inducing apoptosis and ROS generation in vitro and in vivo

Li, L., Li, K., Mao, Y., Qu, H., Yao, B., Zhong, W., Ma, B., & Wang, Z.-Y. (2017) · International Journal of Oncology · doi:10.3892/ijo.2017.4095 · Cited by 42

ROR1 associates unfavorable prognosis and promotes lymphoma growth in DLBCL by affecting PI3K/Akt/mTOR signaling pathway

Mao, Y., Xu, L., Wang, J., Zhang, L., Hou, N., Xu, J., Wang, L., Yang, S., Chen, Y., Xiong, L., et al. (2019) · BioFactors · doi:10.1002/biof.1498 · Cited by 42

Osthole promotes the suppressive effects of cisplatin on NRF2 expression to prevent drug-resistant cervical cancer progression

Su, J., Zhang, F., Li, X., & Liu, Z. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.04.021 · Cited by 42

CoMFA, CoMSIA, Topomer CoMFA, HQSAR, molecular docking and molecular dynamics simulations study of triazine morpholino derivatives as mTOR inhibitors for the treatment of breast cancer

Chhatbar, D. M., Chaube, U., Vyas, V. K., & Bhatt, H. (2019) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2019.04.017 · Cited by 43

Recent advances and future directions in anti‐tumor activity of cryptotanshinone: A mechanistic review

Ashrafizadeh, M., Zarrabi, A., Orouei, S., Saberifar, S., Salami, S., Hushmandi, K., & Najafi, M. (2020) · Phytotherapy Research · doi:10.1002/ptr.6815 · Cited by 42

Germacrone improves liver fibrosis by regulating the PI3K/AKT/mTOR signalling pathway

Ji, D., Zhao, Q., Qin, Y., Tong, H., Wang, Q., Yu, M., Mao, C., Lu, T., Qiu, J., & Jiang, C. (2021) · Cell Biology International · doi:10.1002/cbin.11607 · Cited by 42

Endoscopic Ultrasound Fine-Needle Aspiration Cytology Mutation Profiling Using Targeted Next-Generation Sequencing

Gleeson, F. C., Kipp, B. R., Voss, J. S., Campion, M. B., Minot, D. M., Tu, Z. J., Klee, E. W., Sciallis, A. P., Graham, R. P., Lazaridis, K. N., et al. (2015) · American Journal of Clinical Pathology · doi:10.1309/ajcpu3j7fgayqbrl · Cited by 41

Cryptotanshinone activates AMPK-TSC2 axis leading to inhibition of mTORC1 signaling in cancer cells

Chen, W., Pan, Y., Wang, S., Liu, Y., Chen, G., Zhou, L., Ni, W., Wang, A., & Lu, Y. (2017) · BMC Cancer · doi:10.1186/s12885-016-3038-y · Cited by 41

High Throughput Screening for Natural Host Defense Peptide-Inducing Compounds as Novel Alternatives to Antibiotics

Lyu, W., Deng, Z., Sunkara, L. T., Becker, S. R., Robinson, K., Matts, R. L., & Zhang, G. (2018) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2018.00191 · Cited by 41

PIK3CA gene aberrancy and role in targeted therapy of solid malignancies

Willis, O., Choucair, K., Alloghbi, A., Stanbery, L., Mowat, R. B., Brunicardi, F. C., Dworkin, L. D., & Nemunaitis, J. J. (2020) · Cancer Gene Therapy · doi:10.1038/s41417-020-0164-0 · Cited by 43

Targeting Signaling Pathway Networks in Several Malignant Tumors: Progresses and Challenges

He, H., Shao, X., Li, Y., Gihu, R., Xie, H., Zhou, J., & Yan, H. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.675675 · Cited by 41

Hijacking GPCRs by viral pathogens and tumor

Zhang, J., Feng, H., Xu, S., & Feng, P. (2016) · Biochemical Pharmacology · doi:10.1016/j.bcp.2016.03.021 · Cited by 39

Androgen receptor (AR) signaling promotes RCC progression via increased endothelial cell proliferation and recruitment by modulating AKT → NF-κB → CXCL5 signaling

Guan, Z., Li, C., Fan, J., He, D., & Li, L. (2016) · Scientific Reports · doi:10.1038/srep37085 · Cited by 40

Association of PI3K/AKT/mTOR Pathway with Cancer and Its Therapeutic Implications

Saleem, S., Bashir, I., Khan, M. S., & Ahanger, M. S. (2025) · Springer eBooks · doi:10.1007/978-981-96-2763-9_3 · Cited by 3

Targeting the PI3K pathway in cancer: are we making headway?

Janku, F., Yap, T. A., & Meric-Bernstam, F. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.28 · Cited by 1,033

Targeting the PI3K-AKT-mTOR signaling network in cancer

Khan, K. H., Yap, T. A., Li, Y., & Cunningham, D. (2013) · 癌症：英文版 · doi:10.5732/cjc.013.10057 · Cited by 217

PI3K/AKT/mTOR Signalling Pathways as Therapeutic Targets: From Biomarkers to Clinical Outcomes.

Greshnikov, V. (2026) · Journal of chemical health risks · doi:10.52783/jchr.v16.i2.13542

PI3K/Akt/mTOR inhibitors in cancer: At the bench and bedside

Alzahrani, A. S. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.07.009 · Cited by 1,056